Effects of anti-cardiolipin antibodies and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular disease

References

• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–95
   PubMed Web of Science ®Google Scholar
• Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145: 33–43
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363–9
   PubMed Web of Science ®Google Scholar
• Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J Am Med Assoc 2001; 285: 2481–5
   PubMed Web of Science ®Google Scholar
• Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168–75
   PubMed Web of Science ®Google Scholar
• Pockley AG, Wu R, Lemne C, Kiessling R, de Faire U, Frostegard J. Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension 2000; 36: 303–7
   PubMed Web of Science ®Google Scholar
• Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993; 341: 255–9
   PubMed Web of Science ®Google Scholar
• Hamsten A, Norberg R, Bjorkholm M, de Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1: 113–16
   PubMed Web of Science ®Google Scholar
• Casais P, Meschengieser SS, Gennari LC, Alberto MF, Sanchez-Luceros A, Blanco AN, et al. Antiphospholipid antibodies and hyperhomocysteinaemia in patients with vascular occlusive disease. Thromb Haemost 2006; 96: 19–23
   PubMedGoogle Scholar
• Sherer Y, Shoenfeld Y. Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis. Curr Atheroscler Rep 2001; 3: 328–33
   PubMedGoogle Scholar
• Frostegård J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005; 25: 1776–85
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337–47
   PubMed Web of Science ®Google Scholar
• Hughes GR. The antiphospholipid syndrome. Lupus 1996; 5: 345–6
   PubMed Web of Science ®Google Scholar
• Neville C, Rauch J, Kassis J, Chang ER, Joseph L, Le Comte M, et al. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 2003; 90: 108–15
   PubMedGoogle Scholar
• Kassis J, Neville C, Rauch J, Busque L, Chang ER, Joseph L, et al. Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis. Thromb Haemost 2004; 92: 1312–19
   PubMed Web of Science ®Google Scholar
• Paran D, Fireman E, Levartovsky D, Elkayam O, Kaufman I, Litinsky I, et al. Pulmonary dysfunction in systemic lupus erythematosus and anti-phospholipid syndrome patients. Scand J Rheumatol 2007; 36: 285–90
   PubMed Web of Science ®Google Scholar
• Sallai KK, Nagy E, Bodo I, Mohl A, Gergely P. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. Scand J Rheumatol 2007; 36: 198–205
   PubMed Web of Science ®Google Scholar
• Vazquez-Del Mercado M, Garcia-Cobian TA, Munoz Valle JF, Torres-Carrillo N, Martin-Marquez BT, Arana-Argaez VE, et al. Genotype Ser413/Ser of PAI-2 polymorphism Ser413/Cys is associated with anti-phospholipid syndrome and systemic lupus erythematosus in a familial case: comparison with healthy controls. Scand J Rheumatol 2007; 36: 206–10
   PubMedGoogle Scholar
• Cederholm A, Svenungsson E, Jensen-Urstad K, Trollmo C, Ulfgren AK, Swedenborg J, et al. Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005; 25: 198–203
   PubMed Web of Science ®Google Scholar
• Cederholm A, Frostegård J. Annexin A5 in cardiovascular disease and systemic lupus erythematosus. Immunobiology 2005; 210: 761–8
   PubMed Web of Science ®Google Scholar
• Ravassa S, Bennaghmouch A, Kenis H, Lindhout T, Hackeng T, Narula J, et al. Annexin A5 down-regulates surface expression of tissue factor: a novel mechanism of regulating the membrane receptor repertoire. J Biol Chem 2005; 280: 6028–35
   PubMedGoogle Scholar
• Rand JH, Wu XX, Andree HA, Ross JB, Rusinova E, Gascon-Lema MG, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a ‘lupus procoagulant’ phenomenon. Blood 1998; 92: 1652–60
   PubMed Web of Science ®Google Scholar
• Rand JH. Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome. J Autoimmun 2000; 15: 107–11
   PubMedGoogle Scholar
• Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, et al. Pregnancy loss in the antiphospholipid-antibody syndrome: a possible thrombogenic mechanism. N Engl J Med 1997; 337: 154–60
   PubMed Web of Science ®Google Scholar
• Jahn S, Grunow R, Kiessig ST, Bogacheva GT, Arsenjeva EL, Hlinak A, et al. Cell biology of human IgM-producing hybridomas derived from a fusion of human spleen lymphocytes with mouse myeloma cells. Hybridoma 1987; 6: 679–87
   PubMedGoogle Scholar
• Dunn AS, Kaboli P, Halfdanarson T, Chan H, Hubert R, Rosen S, et al. Do patients followed in anticoagulation clinics for antiphospholipid syndrome meet criteria for the disorder?. Thromb Haemost 2005; 94: 548–54
   PubMedGoogle Scholar
• Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306
   PubMed Web of Science ®Google Scholar
• Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887–93
   PubMed Web of Science ®Google Scholar
• Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23–7
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827–32
   PubMed Web of Science ®Google Scholar
• Sammaritano LR, Ng S, Sobel R, Lo SK, Simantov R, Furie R, et al. Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum 1997; 40: 1998–2006
   PubMed Web of Science ®Google Scholar
• Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109: 797–804
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y. Etiology and pathogenetic mechanisms of the anti-phospholipid syndrome unraveled. Trends Immunol 2003; 24: 2–4
   PubMed Web of Science ®Google Scholar
• Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998; 351: 1467–71
   PubMed Web of Science ®Google Scholar
• Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211–20
   PubMed Web of Science ®Google Scholar
• Dietrich G, Kaveri SV, Kazatchkine MD. Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin Immunol Immunopathol 1992; 62: S73–81
   Google Scholar
• Blank M, Anafi L, Zandman-Goddard G, Krause I, Goldman S, Shalev E, et al. The efficacy of specific IVIg anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 2007; 19: 857–65
   PubMed Web of Science ®Google Scholar
• Krause I, Blank M, Kopolovic J, Afek A, Goldberg I, Tomer Y, et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995; 22: 1068–74
   PubMed Web of Science ®Google Scholar
• Pierangeli SS, Espinola R, Liu X, Harris EN, Salmon JE. Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype. Arthritis Rheum 2001; 44: 876–83
   PubMedGoogle Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747–55
   PubMed Web of Science ®Google Scholar
• Gill V, Doig C, Knight D, Love E, Kubes P. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 2005; 112: 2031–9
   PubMed Web of Science ®Google Scholar
• Vucic S, Chong PS, Dawson KT, Cudkowicz M, Cros D. Thromboembolic complications of intravenous immunoglobulin treatment. Eur Neurol 2004; 52: 141–4
   PubMedGoogle Scholar
• Stenton SB, Dalen D, Wilbur K. Myocardial infarction associated with intravenous immune globulin. Ann Pharmacother 2005; 39: 2114–18
   PubMedGoogle Scholar
• Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005; 16: 313–18
   PubMed Web of Science ®Google Scholar
• Caress JB, Cartwright MS, Donofrio PD, Peacock JE, Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003; 60: 1822–4
   PubMed Web of Science ®Google Scholar
• Sherer Y, Wu R, Kraus I, Peter JB, Shoenfeld Y. Antiphospholipid antibody levels in intravenous immunoglobulin (IVIg) preparations. Lupus 2001; 10: 568–70
   PubMedGoogle Scholar
• Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998; 102: 910–18
   PubMed Web of Science ®Google Scholar
• Thiagarajan P, Benedict CR. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation 1997; 96: 2339–47
   PubMed Web of Science ®Google Scholar
• Ju CW, Wang LS, Yang X, Ma GS, Hua ZC, Gao XY. [A study of human annexin V derivative: its effects of anticoagulation and antithrombosis], in Chinese. Zhonghua Xue Ye Xue Za Zhi 2004; 25: 540–3
   PubMedGoogle Scholar
• Kuypers FA, Larkin SK, Emeis JJ, Allison AC. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 2007; 97: 478–86
   PubMedGoogle Scholar